Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2017

01-11-2017 | Epidemiology

Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women

Authors: María Elena Martínez, Scarlett L. Gomez, Li Tao, Rosemary Cress, Danielle Rodriguez, Jonathan Unkart, Richard Schwab, Jesse N. Nodora, Linda Cook, Ian Komenaka, Christopher Li

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Login to get access

Abstract

Purpose

To assess tumor subtype distribution and the relative contribution of clinical and sociodemographic factors on breast cancer survival between Hispanic and non-Hispanic whites (NHWs).

Methods

We analyzed data from the California Cancer Registry, which included 29,626 Hispanic and 99,862 NHW female invasive breast cancer cases diagnosed from 2004 to 2014. Logistic regression was used to assess ethnic differences in tumor subtype, and Cox proportional hazard modeling to assess differences in breast cancer survival.

Results

Hispanics compared to NHWs had higher odds of having triple-negative (OR = 1.29; 95% CI 1.23–1.35) and HER2-overexpressing tumors (OR = 1.19; 95% CI 1.14–1.25 [HR−] and OR = 1.39; 95% CI 1.31–1.48 [HR+]). In adjusted models, Hispanic women had a higher risk of breast cancer mortality than NHW women (mortality rate ratio [MRR] = 1.24; 95% CI 1.19–1.28). Clinical factors accounted for most of the mortality difference (MRR = 1.05; 95% CI 1.01–1.09); however, neighborhood socioeconomic status (SES) and health insurance together accounted for all of the mortality difference (MRR = 1.01; 95% CI 0.97–1.05).

Conclusions

Addressing SES disparities, including increasing access to health care, may be critical to overcoming poorer breast cancer outcomes in Hispanics.
Literature
1.
Colby SL, Ortman JM (2014) Projections of the size and composition of the U.S. population: 2014 to 2060. In: Current population reports. U.S. Census Bureau, Washington DC
2.
Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, Jemal A (2015) Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin 65(6):457–480CrossRefPubMed
3.
Martinez ME, Nielson CM, Nagle R, Lopez AM, Kim C, Thompson P (2007) Breast cancer among Hispanic and non-Hispanic white women in Arizona. J Health Care Poor Underserved 18(4 Suppl):130–145CrossRefPubMed
4.
Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313(2):165–173CrossRefPubMed
5.
Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK (2002) Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) program population-based study. Arch Intern Med 162(17):1985–1993CrossRefPubMed
6.
Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86(9):705–712CrossRefPubMed
7.
Chen L, Li CI (2015) Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomark Prev 24(11):1666–1672CrossRef
8.
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):1–8CrossRef
9.
Ooi SL, Martinez ME, Li CI (2011) Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat 127(3):729–738CrossRefPubMed
10.
Banegas MP, Li CI (2012) Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women. Breast Cancer Res Treat 134(3):1297–1304CrossRefPubMedPubMedCentral
11.
Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL (2011) The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 117(1):180–189CrossRefPubMed
12.
Cohen RA, Martinez ME (2015) Health Insurance Coverage: early release of estimates from the National Health Interview Survey, January–March 2015. In: National Center for Health Statistics
13.
NAACCR guideline for enhancing Hispanic/Latino identification: Revised NAACCR Hispanic/Latino identification algorithm [NHIA v2.2.1]. In: Group NRaEW. Springfield, IL: North American Association of Central Cancer Registries; 2001
14.
Gomez SL, Glaser SL (2005) Quality of cancer registry birthplace data for Hispanics living in the United States. Cancer Causes Control 16(6):713–723CrossRefPubMed
15.
Keegan TH, John EM, Fish KM, Alfaro-Velcamp T, Clarke CA, Gomez SL (2010) Breast cancer incidence patterns among California Hispanic women: differences by nativity and residence in an enclave. Cancer Epidemiol Biomark Prev 19(5):1208–1218CrossRef
16.
Yang J, Schupp C, Harrati A, Clarke C, Keegan T, Gomez S (2014) Developing an area-based socioeconomic measure from American Community Survey data. Cancer Prevention Institute of California, Fremont
17.
Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12(8):703–711CrossRefPubMed
18.
Banegas MP, Tao L, Altekruse S, Anderson WF, John EM, Clarke CA, Gomez SL (2014) Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California. Breast Cancer Res Treat 144(3):625–634CrossRefPubMedPubMedCentral
19.
Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF (2014) The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr 2014(49):210–217CrossRefPubMedPubMedCentral
20.
Miller BA, Hankey BF, Thomas TL (2002) Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol 155(6):534–545CrossRefPubMed
21.
Martinez ME, Wertheim BC, Natarajan L, Schwab R, Bondy M, Daneri-Navarro A, Meza-Montenegro MM, Gutierrez-Millan LE, Brewster A, Komenaka IK et al (2013) Reproductive factors, heterogeneity, and breast tumor subtypes in women of Mexican descent. Cancer Epidemiol Biomark Prev 22(10):1853–1861CrossRef
22.
Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144(1):1–10CrossRefPubMedPubMedCentral
23.
Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP et al (2015) Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33(20):2254–2261CrossRefPubMedPubMedCentral
24.
Ryan CL, Bauman K (2016) Educational attainment in the United States: 2015. In: Current population reports (P20-578), U.S. Census Bureau, Washington DC
25.
Proctor BD, Semega JL, Kollar MA (2016) Income and poverty in the United States: 2015. In: Current population reports P60-256(RV), U.S. Census Bureau, Washington DC
26.
Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A (2008) Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 58(1):9–31CrossRefPubMed
27.
28.
29.
Keegan TH, Quach T, Shema S, Glaser SL, Gomez SL (2010) The influence of nativity and neighborhoods on breast cancer stage at diagnosis and survival among California Hispanic women. BMC cancer 10:603CrossRefPubMedPubMedCentral
30.
Gomez SL, Le GM, West DW, Satariano WA, O’Connor L (2003) Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace. Am J Public Health 93(10):1685–1688CrossRefPubMedPubMedCentral
31.
Gomez SL, Quach T, Horn-Ross PL, Pham JT, Cockburn M, Chang ET, Keegan TH, Glaser SL, Clarke CA (2010) Hidden breast cancer disparities in Asian women: disaggregating incidence rates by ethnicity and migrant status. Am J Public Health 100(Suppl 1):S125–S131CrossRefPubMedPubMedCentral
32.
Clegg LX, Reichman ME, Hankey BF, Miller BA, Lin YD, Johnson NJ, Schwartz SM, Bernstein L, Chen VW, Goodman MT et al (2007) Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control 18(2):177–187CrossRefPubMed
33.
Gomez SL, Glaser SL (2004) Quality of birthplace information obtained from death certificates for Hispanics, Asians, and Pacific Islanders. Ethn Dis 14(2):292–295PubMed
34.
Metadata
Title
Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women
Authors
María Elena Martínez
Scarlett L. Gomez
Li Tao
Rosemary Cress
Danielle Rodriguez
Jonathan Unkart
Richard Schwab
Jesse N. Nodora
Linda Cook
Ian Komenaka
Christopher Li
Publication date
01-11-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4389-z

Other articles of this Issue 1/2017

Breast Cancer Research and Treatment 1/2017 Go to the issue

Preclinical study

A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy

Letter to the Editor

Letter to the editor: In response to “influence of clinical, societal, and treatment variables on racial difference in ER-/PR- breast cancer survival” by Roseland ME, Schwartz K, Ruterbusch JJ, Lamerato L, Krajenta R, Booza J, Simon MS

Epidemiology

Fatty liver decreases the risk of liver metastasis in patients with breast cancer: a two-center cohort study

Erratum

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Preclinical study

Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution

Preclinical study

Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits